BioKier BKR-013 Clinical Trial

BioKier initiated a clinical trial of BKR-013 colon-targeted capsules in collaboration with Pennington Biomedical Research Center, Baton Rouge, LA. This study will examine the Effect of BKR-013 on Average Daily Glucose Levels.

This trial is registered on www.ClinicalTrials.gov with identifier: NCT03382015, please follow this link for more information. Subject recruitment was initiated January, 2018.

Natural nutrient for improved management of blood glucose in diabetes patients

Type 2 Diabetes and insulin resistance are major health risks, the incidence of which is increasing in all parts of the world

BioKier is developing oral products designed to mimic the effects of malabsorptive gastric bypass surgery which is the most effective treatment for diabetes. In this way, BioKier intends to change the way diabetes is managed and improve the lives of millions of patients worldwide.

BioKier Awarded The $1.6 million Fast-Track Small Business Innovation Research Grant

BioKier has been awarded a $1.6 million Fast-Track Small Business Innovation Research (SBIR) Grant by The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).. Read More

BioKier at 5th Annual World Congress of Food and Nutrition, Kaohsiung, Taiwan

Colonic delivery of nutrients for management of blood glucose in type 2 diabetes patients

BioKier has published an article summarizing our pre-clinical and clinical research: “Colonic delivery of nutrients for management of blood glucose in type 2 diabetes patients”.  The data validate BioKier’s approach to managing glucose using colon-targeted nutrients. This article was published in pear review journal: Functional Foods in Health and Disease. Below you will find link to the article: http://ffhdj.com/index.php/ffhd/article/view/283/574.

What Is BioKier?

BioKier is an early-stage medical food and pharmaceutical company developing new proprietary oral products for people who are not able to manage their glucose.  The product was developed to mimic the mechanism through which metabolic bypass surgery has been proven to improve or resolve diabetes in the significant majority of patients that undergo the bypass surgery for obesity. BioKier’s oral product will potentially also help in managing hypertriglyceridemia, metabolic syndrome, and obesity.

BioKier's Partners

BioKier, Inc. has created a network of partnerships with experts in pharmaceutical development, medical treatment, business strategy, law, and laboratory services. This allows BioKier to utilize specialized guidance and advice at every step of the development process.

Recent News

Colonic delivery of nutrients for management of blood glucose in type 2 diabetes patients

BioKier has published an article summarizing our pre-clinical and clinical research: “Colonic delivery of nutrients for management of blood glucose in type 2 diabetes patients”.  The data validate BioKier’s approach to managing glucose using colon-targeted nutrients. This article was published in pear review journal: Functional Foods in Health and Disease. Below you will find link to the article: http://ffhdj.com/index.php/ffhd/article/view/283/574.
Read More

5th Annual World Congress of Food and Nutrition, Kaohsiung, Taiwan

Dr. George Szewczyk, presented at the 5th Annual World Congress of Food and Nutrition, held November 18-20, 2016, at The Conference Venue – Kaohsiung Exhibition Center in Kaohsiung, Taiwan.
Read More

Target Controlled Delivery of a Small Molecule to the Colon

Dr. Jennifer Law of Encap Drug Delivery, A Division of Capsugel, Livingston, West Lothian, Scotland, United Kingdom…
Read More

Contact Us!